August 9, 2023 07:00 AM EDTUpdated August 10, 10:10 AM

RNA startup ADARx raises $200M from Bain, TCGX to bring RNAi 'to the next level'

Andrew Dunn

Senior Biopharma Correspondent

The RNA startup ADARx Pharmaceuticals has raised a $200 million Series C, aiming to advance multiple clinical programs that directly challenge the leaders of the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

RNA startup ADARx raises $200M from Bain, TCGX to bring RNAi 'to the next level'

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

RNA start­up ADARx rais­es $200M from Bain, TCGX to bring RNAi 'to the next lev­el'

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

RNA startup ADARx raises $200M from Bain, TCGX to bring RNAi 'to the next level'

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market